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Abstract
Background: HLA-C locus products are poorly understood in part due to their low expression
at the cell surface. Recent data indicate that these molecules serve as major restriction elements
for human immunodeficiency virus type 1 (HIV-1) cytotoxic T lymphocyte (CTL) epitopes. We
report here a structure-based technique for the prediction of peptides binding to Cw*0401. The
models were rigorously trained, tested and validated using experimentally verified Cw*0401
binding and non-binding peptides obtained from biochemical studies. A new scoring scheme
facilitates the identification of immunological hot spots within antigens, based on the sum of
predicted binding energies of the top four binders within a window of 30 amino acids.
Results: High predictivity is achieved when tested on the training (r2 = 0.88, s = 3.56 kJ/mol, q2 =
0.84, spress = 5.18 kJ/mol) and test (AROC = 0.93) datasets. Characterization of the predicted
Cw*0401 binding sequences indicate that amino acids at key anchor positions share common
physico-chemical properties which correlate well with existing experimental studies.
Conclusion: The analysis of predicted Cw*0401-binding peptides showed that anchor residues
may not be restrictive and the Cw*0401 binding pockets may possibly accommodate a wide variety
of peptides with common physico-chemical properties. The potential Cw*0401-specific T-cell
epitope repertoires for HIV-1 p24gag and gp160gag glycoproteins are well distributed throughout
both glycoproteins, with thirteen and nine immunological hot spots for HIV-1 p24gag and gp160gag
glycoproteins respectively. These findings provide new insights into HLA-C peptide selectivity,
indicating that pre-selection of candidate HLA-C peptides may occur at the TAP level, prior to
peptide loading in the endoplasmic reticulum.
Background
Major histocompatibility complex (MHC) class I mole-
cules, HLA-A, -B, and -C, are cell surface glycoproteins
consisting of a polymorphic heavy α chain non-covalently
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linked to a light chain, β2-microglobulin (β2m). HLA-A
and -B molecules play critical roles in cell mediated
immune responses by binding short antigenic peptide
fragments and presenting them on the surface of antigen-
presenting cells for recognition by the CD8+ cytotoxic T
lymphocyte (CTL). Although several HLA-C specificities
with CTL epitopes have been reported [1,2], much
remains unknown with regards to their role in the
immune response against viral antigens in part due to
their poor expression at the cell surface [3,4]. Recent
research shows that this group of molecules plays a major
role in the control of human immunodeficiency virus type
1 (HIV-1) infection [5]. Improved understanding of pep-
tide binding to this group of molecules is important in the
study of HIV-1 disease progression, as well as the design
of effective HIV peptide vaccines.
The HLA-C allele, Cw*0401, is of particular interest in the
study of HIV-1 disease progression because it is the restric-
tion element for HIV-1 proteins [5]. Two HIV-1 proteins
(p24gag and gp160gag) are currently known to be restricted
by Cw*0401 [5]. Cw*0401 is present in approximately
10% of the general population [6]. The allele is expressed
intracellularly in amounts comparable with HLA-A and -B
molecules, but is poorly expressed at the cell surface [7,8].
Improved understanding of peptide binding to this mole-
cule is important for elucidating its role in HIV-1 disease
progression.
Computational strategies for prediction of peptide bind-
ing to HLA-A and -B molecules are relatively advanced [9],
while sequence-based predictive models for HLA-C mole-
cules have encountered limited success due to the lack of
experimental training data [10]. Two matrix-based predic-
tion algorithms for Cw*0401 were reported [11,12], but a
sequence independent approach is still lacking. To over-
come these limitations, we have developed a structure-
based predictive technique that integrates the strength of
Monte Carlo simulations and homology modeling [13-
15]. This method utilizes a probe or "base fragment" to
sample different regions of the receptor binding site, fol-
lowed by loop closure and refinement of the entire class I
peptide. The technique has been successfully applied to
analyze peptides binding to a variety of MHC class II alle-
les [14,15]. In this work, we now extend our analysis to
peptides presented by the class I HLA-C molecule. We
investigated the HIV-1 p24gag and gp160gag peptide bind-
ing repertoire of Cw*0401 and illustrate that areas with
high concentration of T-cell epitopes or "immunological
hot spots" are potentially well distributed throughout
both HIV-1 p24gag  and gp160gag. We also show that
Cw*0401 can possibly bind antigenic peptides in
amounts comparable to both HLA-A and -B molecules.
Characterization of predicted Cw*0401 binding
sequences reveal that Cw*0401 may bind a large variety of
amino acids at anchor positions with common physico-
chemical properties which correlate well with existing
experimental studies [11].
Results and discussion
Cw*0401 predictive model
High predictivity (r2 = 0.88, s = 3.56 kJ/mol, q2 = 0.84,
spress = 5.18 kJ/mol) is achieved when tested on the train-
ing dataset of 6 Cw*0401 peptide sequences. The
Cw*0401 predictive model outperforms the predictive
models done by Rognan et al. [16] on training datasets of
5 A*0204 (r2 = 0.85, spress = 2.40 kJ/mol) and 37 2Kk (r2 =
0.78, spress = 3.16 kJ/mol) peptide sequences and is compa-
rable with our previous DRB1*0402 (r2 = 0.90, s = 1.20 kJ/
mol, q2 = 0.82, spress = 1.61 kJ/mol) and DQB1*0503 (r2 =
0.95, s = 1.20 kJ/mol, q2 = 0.75, spress = 2.15 kJ/mol) pre-
diction models on a training set of 8 peptides [17]. The
cross-validation coefficient q2 and the standard error of
prediction spress are stable, with q2 = 0.84 and spress = 5.18 kJ/
mol. This iterative regression procedure validates the
internal consistency of the scoring function in the current
model, rendering it suitable for predictions on the test
dataset obtained from biochemical studies. The predictive
performance of our model is further validated using the
test dataset of 58 peptides. The external validation results
indicate that our Cw*0401 predictive model is suitable
for discriminating binding ligands from the background
with high accuracy (AROC = 0.93) with sensitivity of 76%
(SP = 0.95).
Characterization of Cw*0401 binding peptides
An in-depth analysis was performed to investigate the
characteristics of Cw*0401 binding peptides. A panel of
2279 sequences was generated using an overlapping slid-
ing window of size 9 across the entire p24gag [5] and
gp160gag [18] glycoproteins and modeled into the binding
groove of Cw*0401. From these sequences, a total of 877
binding sequences (predicted binders; SE = 76%, SP =
80%) were selected and a systematic analysis was per-
formed to analyze the number of occurrence of individual
amino acid residues and physico-chemical properties [19]
at each position of Cw*0401 binding peptides.
Peptide position p2 is characterized by alanine (10%),
glycine (13%), leucine (9%), serine (9%). 60% of the pre-
dicted residues at this position are hydrophobic in nature,
while 93% are neutral. These properties correlate with the
physico-chemical properties of existing binding motif
(Tyr/Phe) at p2 [11] as well as with the observed conser-
vation in the test data (Table 1: Phe – 58% and Tyr –
26%). The p3 position shows a strong preference for gly-
cine (11%) and threonine (8%). Existing anchor residues
at this position are aspartic acid and histidine, which
accounts for 9% of the total position-specific composition
in the dataset. The p4 position shares similar characteris-Immunome Research 2007, 3:7 http://www.immunome-research.com/content/3/1/7
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tics as p3 (glycine: 9%; threonine: 8%), with additional
preference for leucine (8%). Similar results were obtained
at the p5 position (alanine: 8%; glycine: 9%; leucine: 8%).
At p6, characteristic residues include glycine (9%) and
leucine (8%). This position is favored by neutral (81%)
acyclic (89%), medium/large (77%), and hydrophobic
(51%) residues. The physico-chemical properties of these
residues are in agreement with Val/Ile/Leu as reported in
earlier studies [11] and is comparable with the conserva-
tion in the test dataset reported in Table 1 (Val – 29%, Ile
– 12%, Leu and Pro – 10%). Finally, the p9 position was
defined by six amino acids, including alanine (8%), gly-
cine (10%), isoleucine (8%), leucine (8%), threonine
(9%), and valine (8%). This position is primarily domi-
nated by neutral (90%) and hydrophobic (58%) residues,
and agrees with profiles of Leu/Phe as previously reported
[11] and is consistent with the conservation in the test
dataset reported in Table 1 (Leu and Phe – 39%,). Collec-
tively, our data indicates that individual binding pockets
may not be highly specific as previously reported [11] but
can rather accommodate a wide-range of anchor residues
with common physico-chemical properties. We attribute
the discrepancies to two possibilities: i) the lack of exten-
sive research on Cw*0401 peptides; and ii) natural pep-
tides carrying these residues may be present in small
amount and were thus not detected by experimental stud-
ies.
Prediction of p24gag and gp160gag immunological hot spots
The potential T-cell epitope repertoire (data not shown)
and immunological hot spots (Figure 1) for HIV-1 p24gag
and gp160gag are well distributed throughout both glyco-
Predicted Cw*0401-specific immunological hotspots for p24gag and gp160gag 
Figure 1
Predicted start positions of Cw*0401-specific hotspots (sliding window size = 30) along (A) p24gag and (B) gp160gag glycopro-
teins. Scores are computed based on the sum of predicted binding energies of top four binders within the 30 amino acid sliding 
window. Predicted hotspots regions are shown in blue boxes with experimentally verified regions shown in red.Immunome Research 2007, 3:7 http://www.immunome-research.com/content/3/1/7
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Table 1: HLA-Cw4 dataset used in this study.
No. Category Source Peptide IC50 (nM) Ref.
1 Training Set Cw3 consensus FAMPNFQTL 651 24
2 Training Set Cw6 consensus IPFPIVRYL >30000 24
3 Training Set Cw7 consensus KYPDFVDAL 2.4 24
4 Training Set Cw4 consensus QYDDAVYKL 18 24
5 Training Set Histone H3.3 RYRPGTVAL >30000 24
6 Training Set Unknown Cw6 natural ligand YQFTGIKKY >30000 24
7 Test Set Transcripton factor SUPT4H 56–64 SFDGIIAMM Binder 10
8 Test Set Transducin-like 3 120–128 AFDPTSTLL Binder 10
9 Test Set UBE3B variant 1 742–750 VFDPALNLF Binder 10
10 Test Set XP_173235 3–11 LFDITGQDF Binder 10
11 Test Set 8 59–67 VYDTNPAKF Binder 10
12 Test Set Acyl-CoA synthetase 4 82–90 LFDHAVSKF Binder 10
13 Test Set Adenosylhomocyteinehydrolase 566–574 SFDAHLTEL Binder 10
14 Test Set ART-1 Adenocarcinoma antigen 21–29 SFDLLPREF Binder 10
15 Test Set ATP-binding cassette, sub-family F, member 3 500–508 YYDPKHVIF Binder 10
16 Test Set Block of proliferation 1 639–647 SYDSKLVWF Binder 10
17 Test Set BM-015 144–152 HFDPEVVQI Binder 10
18 Test Set CDC45 541–549 HFDLSVIEL Binder 10
19 Test Set Cholesterol acyltransferase 72–80 HFDDFVTNL Binder 10
20 Test Set Chromosome 20 open reading frame 40 318–326 FFDNISSEL Binder 10
21 Test Set Elongation factor 2 265–273 YFDPANGKF Binder 10
22 Test Set Epithelial cell transforming oncogene 21–29 IFDSKVTEI Binder 10
23 Test Set Ethanolamine kinase EKI1 132–141 HWDPQEVTL Binder 10
24 Test Set Eukaryotic translation initiation factor 3, Su 6 interacting protein 478–486 FLDLTEGEF Binder 10
25 Test Set Fatty acid synthetase 544–552 TFDDIVHSF Binder 10
26 Test Set FK506 binding protein 9 303–311 VFDIHVIDF Binder 10
27 Test Set Glutamine:fructose-6-phosphate amidotransferase (GFAT) 345–353 NFDDYTVNL Binder 10
28 Test Set Tousled-like kinase 456–464 AFDLTEQRY Binder 10
29 Test Set Transcription factor IIE 144–152 LFDPMTGTF Binder 10
30 Test Set HSP 70 kDa 1A 179–205 IFDLGGGTF Binder 10
31 Test Set HSPC198 19–27 SYDLFVNSF Binder 10
32 Test Set HSP J2 156–164 SFDTGFTSF Binder 10
33 Test Set Hypothetical protein FLJ00365 80–88 YFDAIPVTM Binder 10
34 Test Set Hypothetical protein FLJ11220 373–381 YLPDFLDYF Binder 10
35 Test Set Hypothetical protein FLJ20343 415–423 RFDEAYIYM Binder 10
36 Test Set Insuline degrading enzyme IDE 150–158 YFDVSHEHL Binder 10
37 Test Set Integrin alpha-V (Vitronectin) 224–232 KYDPNVYSI Binder 10
38 Test Set KCIP-1 186–194 AFDEAIAEL Binder 10
39 Test Set KIAA0461 721–729 SMDPLPVFL Binder 10
40 Test Set KIAA1463 444–452 FYDERIVVV Binder 10
41 Test Set KIAA1921 350–358 VYDGKIYTL Binder 10
42 Test Set Metalloproteinase 10 331–339 FWPSLPSYL Binder 10
43 Test Set Methionine-tRNA synthetase 2 (mitochondrial) 58–66 YYDEKVVKL Binder 10
44 Test Set Mucin-5B 168–176 TFDGTSYTF Binder 10
45 Test Set Myosin phosphatase target subunit 1 37–45 KFDDGAVFL Binder 10
46 Test Set Nuclear autoantigenic sperm protein 599–607 QYDEAVAQF Binder 10
47 Test Set Nucleoporin NUP358 261–269 SFDSALQSV Binder 10
48 Test Set P621 70–78 VFDKTLAEL Binder 10
49 Test Set Phosphate carrier precursor 331–339 IYDSVKVYF Binder 10
50 Test Set PRO2242 61–69 YFDPQYFEF Binder 10
51 Test Set Protein phosphatase 6 102–110 KWPDRITLL Binder 10
52 Test Set Putative prostate tumor suppressor 165–173 TFDLQRIGF Binder 10
53 Test Set Rac1 168–176 VFDEAIRAV Binder 10
54 Test Set RNA Helicase A 697–705 VFDPVPVGV Binder 10
55 Test Set Similiar to KIAA1911 80–88 FWDGKIVLV Binder 10
56 Test Set Topoisomerase I 241–249 YYDGKVMKL Binder 10
57 Test Set Tensin 3 143–151 FYDDKVSAL Binder 10
58 Test Set HIV-1 (BRU) gp120 350–358 SFNCGGEFF Binder 18
59 Test Set HIV-1 (BRU) gag p24 307–315 QASQEVKNW Binder 21
60 Test Set Synthetic peptide AYDDAVYKL Binder 25
61 Test Set Cw7 consensus AYADFVYAY >30000 24
62 Test Set CKShs2 KYFDEHYEY >30000 24
63 Test Set Unknown Cw6 natural ligand YRHDGGNVL >30000 24
64 Test Set Unknown Cw7 natural ligand NKADVILKY >30000 24Immunome Research 2007, 3:7 http://www.immunome-research.com/content/3/1/7
Page 5 of 8
(page number not for citation purposes)
Table 3: Predicted Cw*0401-specific immunological hotspots for gp160gag.
No
.
Position Sequence
1 44–89 VWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNV
2 102–171 EQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLGNATNTNSSNTNSSSGEMM
MEKGEIKNCSFNISTSIR
3 174–289 VQKEYAFFYKLDIIPIDNDTTSYTLTSCNTSVITQACPKVSFEPIPIHYCAP
AGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVI
RSANFTDNAKTI
4 341–504 AKWNATLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNS
TQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQFINMWQEVGKAMYAPPI
SGQIRCSSNITGLLLTRDGGNNNNGSEIFRPGGGDMRDNWRSELYKYKVVKI
EPLGVAPT
5 489–559 KYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGARSMT
LTVQARQLLSGIVQQQNN
6 581–639 LQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNNMT
WMEWDRE
7 667–721 ELDKWASLWNWFNITNWLWYIKIFIMIVGGLVGLRIVFAVLSIVNRVRQGYS
PLS
8 708–766 SIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLA
LIWDDLR
9 793–852 RGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRA
IRHIPRRI
Table 2: Predicted Cw*0401-specific immunological hotspots for p24gag.
No. Position Sequence
1 20–75 RLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSE
EL
2 89–148 YNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY
PIVQNIQGQMVHQAIS
3 143–262 PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNT
MLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTT
STLQEQIGWMTNNPPIPVGEIY
4 311–381 QEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLA
EAMSQVTNSATIMMQRG
5 447–506 EFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQVTLWQRPLVT
IKIGGQ
6 526–590 LPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLT
QIGCTLNFPIS
7 664–727 FRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAF
TIPSINNETP
8 708–791 DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQ
NPDIVIYQYMDDLYVGSDLEIGQHRTKIEE
9 873–930 TKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTY
QIYQ
10 996–1053 TWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRG
RQKV
11 1054–1157 VTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESELVNQ
IIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDE
12 1157–1316 DEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQL
DCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDN
GSNFTGATVRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQA
13 1308–1368 IIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQ
KQITKIQ
14 1378–1427 RNPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCImmunome Research 2007, 3:7 http://www.immunome-research.com/content/3/1/7
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proteins. The known p24gag epitope (p24 168–175) and
gp160gag epitope (gp160 375–383) were successfully pre-
dicted by our model at the threshold of -200 (SE = 76%,
SP = 80%) [5,20]. At this threshold, the number of pre-
dicted hot spots for p24gag are fourteen (p24 20–75, 89–
148, 143–262, 311–381, 447–506, 526–590, 664–727,
708–791, 873–930, 996–1053, 1054–1157, 1157–1316,
1308–1368, and 1378–1427), with an estimated FN = 3,
and FP = 3 for SE = 0.76 and SP = 0.95 (Figure 1 and Table
2). For gp160gag we predict nine hot spots (gp160 44–89,
102–171, 174–289, 341–504, 489–559, 581–639, 667–
721, 708–766, and 793–852), with an estimated FN = 2,
FP = 2 for SE = 0.76 and SP = 0.95 (Figure 1 and Table 3).
The results presented here indicate that Cw*0401 can
bind antigenic peptides with specificities comparable to
HLA-A and -B molecules, and any variability in antigen
expression may be directly related to the loss or reduced
cell surface expression of the molecule by mechanisms as
yet unknown [8,21].
Conclusion
Due to the low expression of HLA-C molecules at the cell
surface, their role in cell mediated immune responses
remain poorly understood. Collectively, the outcome of
this analysis provides insights into the binding specifici-
ties of Cw*0401. Our data strongly indicate that
Cw*0401 can bind antigenic peptides in amounts compa-
rable to both HLA-A and -B molecules, and show the exist-
ence of a potentially large number of Cw*0401-specific T-
cell epitopes that are evenly distributed throughout both
HIV-1 p24gag and gp160gag glycoproteins. It remains to be
determined what proportion of these peptides may be
expressed at the cell surface and capable of eliciting func-
tional responses. Probably, pre-selection of candidate
HLA-C peptides may occur at the TAP level, prior to pep-
tide loading in the ER [8]. Consequently, a higher concen-
tration of peptides is necessary for complexation with
HLA-C molecules, resulting in their release from TAP. This
provides a possible explanation for the reduced cell sur-
face expression of HLA-C molecules [8].
Methods
Data
Crystallographic data
The coordinates of Cw*0401 were obtained from the Pro-
tein Databank (PDB) with PDB code 1QQD [22]. The
structure was relaxed by conjugate gradient minimization,
using the Internal Coordinate Mechanics (ICM) software
[23].
Experimental binding data
The dataset comprises a total of 64 (57 binders and 7 non-
binders) 9-mer peptides (Table 1). The available dataset is
divided into training and testing datasets. Peptides with
experimental IC50 values were selected as training data for
optimizing the empirical free energy function (refer
Empirical Free Energy Function). Due to the lack of experi-
mental data, only 9 peptides with experimental IC50 val-
ues were identified, six (three binders and three non-
binders) of which were used for training, while the
remainder (four non-binders) were included in the test
dataset as true negatives. Therefore, the training dataset
contained six peptides with experimentally determined
IC50 values (2 high-affinity binders, 1 medium-affinity
binder, and 3 non-binders) derived from biochemical
studies [24], while the testing dataset comprised the
remainder 58 peptides (54 binders and 4 non-binders)
[10,18,21,24,25]. Experimental IC50 values were classified
as follows – high-affinity binders: IC50  ≤ 500 nM,
medium-affinity binders: 500 nM < IC50 ≤ 1500 nM, low-
affinity binders: 1500 < IC50 ≤ 5000 nM and non-binders:
5000 < IC50.
HIV-1 sequence data
The sequences of HIV-1 p24gag and gp160gag glycoproteins
were obtained from UniProt [26]. The accession numbers
for p24gag and gp160gag glycoproteins used in this study
are P04585 and P03377 respectively.
Model
Peptide docking
Docking was performed according to the procedure uti-
lized in previous similar works [13-15]: (i) pseudo-
Brownian rigid body docking of peptide fragments to the
ends of the binding groove, (ii) central loop closure by
satisfaction of spatial constraints, and (iii) refinement of
the backbone and side-chain atoms of the ligand and
receptor contact regions.
Empirical free energy function
The scoring function presented herein is based on the free
energy potential in ICM [23]. Computation of the binding
free energy was performed according to previous similar
work based on the difference between the energy of the
solvated complex and the sum of the energy of the sol-
vated receptor and that of the peptide ligand, followed by
optimization using experimental IC50 values [15]. This
step was followed by 6-fold cross-validation for assess-
ment of quality of the scoring function [15]. In k-fold
cross-validation, k random, (approximately) equal-sized,
disjoint partitions of the sample data were constructed,
and all given models were trained on (k-1) partitions and
tested on the excluded partition. The results were averaged
after k such experiments, and thus the observed error rate
may be taken as an estimate of the error rate expected
upon generalization to new data. The predictive power of
the models was assessed by the cross-validation coeffi-
cient q2 and the standard error of prediction spress.Immunome Research 2007, 3:7 http://www.immunome-research.com/content/3/1/7
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Immunological hot spot prediction
In this study, 'immunological hot spots' are defined as
antigenic regions of up to 30 amino acids and modeled
according to previous similar work based on the sum of
predicted binding energies of the top four binders within
a window of 30 amino acids [27]. Where available, these
predicted hotspots were validated with available experi-
mentally determined sites.
Training, testing and validation
The free energy scoring function was calibrated using 6
peptides with experimental IC50 values and tested on a
dataset 58 peptides (54 binders and 4 non-binders)
obtained from biochemical studies (Table 1). The predic-
tive performance of our model was assessed using sensi-
tivity (SE), specificity (SP) and receiver operating
characteristic (ROC) analysis [28]. SE = TP/(TP+FN) and
SP = TN/(TN+FP), indicate percentages of correctly pre-
dicted binders and non-binders, respectively. TP (true
positives) represents correctly predicted experimental
binders and TN (true negatives) for experimental non-
binders incorrectly predicted as binders. FN (false nega-
tives) denotes experimental binders predicted as non-
binders and FP (false positives) stands for experimental
non-binders predicted as binders. The accuracy of our pre-
dictions was assessed by the ROC analysis where the ROC
curve is generated by plotting SE as a function of (1-SP)
for a complete range of classification thresholds. The area
under the ROC curve (AROC) provides a measure of overall
prediction accuracy, AROC < 70% for poor, AROC > 80% for
good and AROC > 90% for excellent predictions [15].
Abbreviations
CTL, cytotoxic T lymphocyte; HLA, human leukocyte anti-
gen; MHC, major histocompatibility complex; ER, endo-
plasmic reticulum; HIV, human immunodeficiency virus;
ROC, receiver operating characteristic; SE, sensitivity; SP,
specificity; TN, true negative; TP, true positive; FN, false
negative; FP, false positive
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